Vaxart (NASDAQ:VXRT) Stock Price Passes Below 200 Day Moving Average – Here’s Why

Vaxart, Inc. (NASDAQ:VXRT)’s stock price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.39 and traded as low as $0.3550. Vaxart shares last traded at $0.37, with a volume of 277,536 shares traded.

Vaxart Stock Up 1.8%

The firm has a market cap of $88.83 million, a price-to-earnings ratio of -1.37 and a beta of 0.88. The company has a 50 day moving average of $0.36 and a 200 day moving average of $0.39.

Hedge Funds Weigh In On Vaxart

Several institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace LLP acquired a new stake in Vaxart in the second quarter worth $794,000. Jones Financial Companies Lllp grew its position in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 478,111 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Vaxart in the 1st quarter worth about $56,000. Goldman Sachs Group Inc. acquired a new position in Vaxart during the 1st quarter valued at about $31,000. Finally, Creative Planning acquired a new position in Vaxart during the 2nd quarter valued at about $33,000. 18.05% of the stock is currently owned by hedge funds and other institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.